- Asia Beat: Enlightened Astellas in need of transcendental Medivation?
- Enzalutamide moves forward for chemo-naive prostate cancer
- Xtandi and deliver: US FDA OK's Medivation/Astellas mCRPC drug in record time
- New clinical data add to Xtandi's luster
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.